These findings demonstrate the commonly applied inhibitors of human DOPA decarboxylase in levodopa combination therapy do not inhibit bacterial TDC dependent levodopa conversion, implying levodopa/carbidopa (levodopa) combination therapy for PD patients would not affect the efficacy of levodopa in situ by small intestinal bacteria. Here, DDC is linked to Parkinson disease.